Medical Hypnosis and Music for Palliative Care (MuzhypforPC)

November 25, 2024 updated by: Josiane Bissonnette, Laval University

Feasibility and Efficacy of Hypnosis and Music on Pain, Anxiety and Well-being in End-of-life Palliative Care at Home

The goal of this randomized controlled trial is to evaluate the efficacy of a personalized multimodal intervention program (MuzHyp) including hypnosis, music or their combination to improve palliative care at home.

The main objective is to evaluate if the intervention program will significantly reduce participants' composite score of pain, anxiety, and unwellness as evaluated by the Edmonton symptom assessment scale (ESAS) immediately after the intervention, and whether this improvement will be significantly greater than that of control sessions.

Study Overview

Detailed Description

Context :

Quality of life at home in end-of-life palliative care is an ideal that is often difficult to achieve. Side effects of medications and limited access to resources and services can affect the control of pain, anxiety and well-being. Research shows that musical interventions and the use of medical hypnosis can help reduce pain and anxiety, and thus improve patients' psychological well-being in many clinical settings. In view of this, we have developed an intervention program combining medical hypnosis and music (Bissonnette et al., 2022; https://www.frontiersin.org/articles/10.3389/fpain.2022.926584/full).

Objectives and study design :

The main objective of this randomized control trial is to evaluate the efficacy of a personalized multimodal intervention program including hypnosis, music or their combination on composite score of pain, anxiety and unwellness as evaluated with the ESAS.

The secondary objectives are to assess :

  • The evolution of distress and of each of the ESAS variables (pain, fatigue, nausea, depression, anxiety, sleepiness, appetite, unwellness, breathlessness) from pre-test to post-test compared with changes in these variables in the control group.
  • The preference for the intervention modality (hypnosis, music or their combination).
  • The feasibility of the experimentation in end-of-life palliative care at home.
  • The experiential dimensions associated with music and hypnosis
  • The subjective experience of the intervention.

Description of interventions :

The intervention program consists of a personalized multimodal intervention involving hypnosis and music. It offers each participant the option to receive (a) the hypnosis intervention presented as guided imagery, (b) the music intervention, or (c) a combination of (a) hypnosis (guided imagery) and (b) music. Each intervention is further personalized by integrating individually preferred imagery and/or music.

Recruitment and allocation procedure :

Adults (n = 40) in palliative home care receiving home support services from CIUSSS-NIM or CISSS-CA and meeting the inclusion criteria are eligible to participate in the project. The clinical team identifies participants who meet the selection criteria and asks them if they would like a visit from a member of the research team. During this visit, each participant is informed of the project and asked to sign the consent form. All participants then choose their preferred intervention modality (a. hypnosis, b. music or c. combination of hypnosis and music) before completing baseline measures including a socio-demographic questionnaire, the ESAS and a distress measure. Participants who choose an intervention with music (modalities a and c) are asked to identify pieces that they expect will generate positive emotions. Participants who choose guided imagery (modalities b and c) are asked to describe a pleasant place.

Participants are then stratified by gender and randomly assigned to the "experimental" group and the "control/waiting list" group. The distribution follows the order previously determined by a random table generated using an Excel function.

Two sessions are offered to the participants of the experimental group. During the sessions, a facilitator takes the pre-interventions measurements (see below), asks the participants to listen to the recorded intervention of 15 to 25 minutes by themselves while he/she waits outside the participant's home, and then comes back to fill in the post-intervention measurements (see below). Participants are also asked to report how they feel after each intervention and are given a brief semi-structured interview about their subjective experience.

Procedure in the two intervention sessions:

  1. Measures (ESAS; Distress) (3-5 min)
  2. Intervention Sessions (15-25 minutes)
  3. Measures (ESAS; Distress; Experiential dimensions) (3-5 minutes)
  4. Semi-structured interview about the subjective experience (2-5 min)

Participants in the control/waiting list group receive two control sessions following the same procedure as the experimental group but without receiving the intervention. During these control sessions, the same distress and ESAS measures are taken at 20-minute intervals. In the meantime, participants continue to perform their usual daily activities by themselves while the experimenter walk outside the participant's home.

Plan for each control session:

  1. Measures (ESAS; Distress) (3-5 min)
  2. Usual Daily Activities (20 min)
  3. Measures (ESAS; Distress) (3-5 min)

After the two control sessions are completed, participants in the control/waiting list group receive two intervention sessions, following the same procedure as the experimental group. These supplementary sessions are not part of the main analysis design but will be examined as they provide additional pre-post intervention data.

Main objective:

To analyze the changes in the composite score of pain, anxiety, and unwellness between the beginning and the end of the sessions as a function of the group (control/waiting list vs. experimental), a mixed model repeated measures analysis procedures will be performed using SPSS software (GLM model). Data from all participants who completed at least one session will be retained and included in the analyses. Missing scores will be imputed by the model. We have also planned a sensitivity analysis taking into account the baseline level of the dependent variables, if there is a risk of a floor effect.

The data acquired in the additional sessions for the control group will be analysed separately and compared to the pre-post data obtained in sessions 1 and 2 in the same participants and in the experimental group.

The secondary objectives:

To assess the evolution of distress and of each of the ESAS variables of the experimental group from pre- to post-intervention and to evaluate the composite score for the intervention sessions in the control/ waiting list group we will apply a similar GLM model.

To assess the preference of the intervention modality (hypnosis, music, or hypnosis and music), we will count the frequency of selection of each intervention modality for all participants.

To assess the experiential aspects of the intervention, we will calculate the mean for each of the eight experiential dimensions.

To explore the subjective experience of the intervention, two open questions will be asked by the facilitator to inquire about the participant's current feeling and about their impression of change.

Study Type

Interventional

Enrollment (Actual)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Quebec
      • Montréal, Quebec, Canada
        • Ciusss-Nim
      • Saint-Georges, Quebec, Canada
        • CISSS-CA

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • End-of-life palliative care at home
  • Between 30% and 79% on the Karnofsky Performance Index
  • With adequate communication skills to complete the steps of the research
  • With satisfactory or corrected hearing, as recommended by the caregiver.
  • Severe neurocognitive or psychotic disorders

Exclusion Criteria:

  • Severe neurocognitive or psychotic disorders

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Personalized multimodal intervention involving hypnosis and/or music

This arm will receive a personalized multimodal intervention involving (a) hypnosis, (b) music or (c) hypnosis and music.

Note that the objective of the research is not to compare the effect of the different intervention modalities between them, but to consider these three modalities as a multimodal intervention taking into consideration patients' preferences, that we compare to the control.

The three intervention modalities (music and/or hypnosis) will begin by a moment of relaxation in which we will ask the participants to focus their attention on their breathing, on relaxation and on the process of absorption into oneself. The hypnosis modality consists in visiting in imagination a pleasant place that the participant will choose and to live some metaphorical stories. The "musical" modality consists of listening to one or two pieces of music chosen by each participant and which brings him/her well-being, according to them. These two types of work will be preceded by a moment of relaxation in which we will ask the participants to focus their attention on their breathing, on relaxation and on the process of absorption into oneself.
Other Names:
  • MuzHyp program
  • Hypnosis and music intervention program
No Intervention: Control/Waiting list
The participants of the control group will carry out its their daily activities and will be assessed using the same measures, at the beginning of each session and after a delay comparable to the duration of the intervention administered in the experimental group.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in Composite pain, anxiety, and unwellness score
Time Frame: The posttest was administered 25 minutes after the pretest.
Change in composite outcome score for pre-test to post-test for the experimental sessions compared with change in the control group. The composite score will be obtained by summing the pain (0-10), anxiety (0-10) and unwellness scores (0-10) from the Edmonton Symptom Assessment Scale. (ESAS)
The posttest was administered 25 minutes after the pretest.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in Pain levels
Time Frame: The posttest was administered 25 minutes after the pretest.
Change in pain level, as assessed by the Edmonton Symptom Assesment Scale (ESAS) on a scale of 0 to 10.
The posttest was administered 25 minutes after the pretest.
Changes in Anxiety levels
Time Frame: The posttest was administered 25 minutes after the pretest.
Change in anxiety level, as assessed by the Edmonton Symptom Assesment Scale (ESAS) on a scale of 0 to 10.
The posttest was administered 25 minutes after the pretest.
Changes in Unwellness levels
Time Frame: The posttest was administered 25 minutes after the pretest.
Change in unwellness level, as assessed by the Edmonton Symptom Assesment Scale (ESAS) on a scale of 0 to 10.
The posttest was administered 25 minutes after the pretest.
Changes in Fatigue levels
Time Frame: The posttest was administered 25 minutes after the pretest.
Change in fatigue level, as assessed by the Edmonton symptom assesment scale (ESAS) on a scale of 0 to 10.
The posttest was administered 25 minutes after the pretest.
Changes in Nausea levels
Time Frame: The posttest was administered 25 minutes after the pretest.
Change in nausea level, as assessed by the Edmonton Symptom Assesment Scale (ESAS) on a scale of 0 to 10.
The posttest was administered 25 minutes after the pretest.
Changes in Depression levels
Time Frame: The posttest was administered 25 minutes after the pretest.
Change in depression level, as assessed by the Edmonton Symptom Assesment Scale (ESAS) on a scale of 0 to 10.
The posttest was administered 25 minutes after the pretest.
Changes in Sleepiness levels
Time Frame: The posttest was administered 25 minutes after the pretest.
Change in sleepiness level, as assessed by the Edmonton Symptom Assesment Scale (ESAS) on a scale of 0 to 10.
The posttest was administered 25 minutes after the pretest.
Changes in Appetite
Time Frame: The posttest was administered 25 minutes after the pretest.
Change in appetite level, as assessed by the Edmonton Symptom Assesment Scale (ESAS) on a scale of 0 to 10.
The posttest was administered 25 minutes after the pretest.
Changes in Distress
Time Frame: The posttest was administered 25 minutes after the pretest.
Change in distress level, as assessed by a Distress Thermometer on a scale of 0 to 10.
The posttest was administered 25 minutes after the pretest.
Preference of the intervention modality
Time Frame: At baseline
The preference of the intervention modality by calculating the selection frequency (and the percentage) of each intervention across all participants.
At baseline
Experiential dimensions
Time Frame: 1 week
Ratings (0-10) obtained to characterize a) the participant's experience of mental absorption, b) change in perspective, c) experience of reminiscence, d) feeling of being understood, e) experience of transcendence, f) somatic experience, g) feeling of being in control
1 week
Feasibility of the study
Time Frame: Through study completion, an average of 1 year.
To conduct the feasibility study, we will look at 1) the number of patients who have expressed initial interest in the study; 2) the number of participants recruited per month, 3) the proportion of patients who participate in the study out of the number of people in palliative home care for the entire experimental period, 4) the proportion of patients who complete the study.
Through study completion, an average of 1 year.

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Subjective experience
Time Frame: 1 week
Two open questions will be asked by the facilitator to inquire about the participant's current feeling (How do you feel?) and about their impression of change (What is different now compared to the beginning of the session?). The answers will be audio-recorded or noted by the facilitator.
1 week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Josiane Bissonnette, Ph.D, Laval University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 13, 2022

Primary Completion (Actual)

August 31, 2023

Study Completion (Actual)

August 31, 2023

Study Registration Dates

First Submitted

July 3, 2023

First Submitted That Met QC Criteria

July 10, 2023

First Posted (Actual)

July 19, 2023

Study Record Updates

Last Update Posted (Estimated)

November 27, 2024

Last Update Submitted That Met QC Criteria

November 25, 2024

Last Verified

November 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • MP-23-2022-896

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Anxiety

Subscribe